注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
SAGE Therapeutics Inc是一家生物制药公司。该公司专注于脑保健药物的开发和商业化。该公司的产品ZULRESSO(brexanolone)CIV注射剂用于治疗成人产后抑郁症(PPD)。该公司拥有一系列其他候选产品,重点是调节两个中枢神经系统(CNS)受体系统,即GABA和NMDA。该公司针对大脑疾病和失调,重点关注三个领域:抑郁症、神经病学和神经精神病学。其另一个先进的候选产品是zuranolone (SAGE-217),这是一种针对某些情感障碍开发的口服化合物,包括重度抑郁症(MDD)和PPD。Zuranolone是一种神经活性类固醇,是GABAA受体的正变构调节剂,靶向突触和突触外GABAA受体。该公司拥有一系列针对GABAA受体的其他化合物,包括SAGE-324。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Barry E. Greene | 58 | 2020 | President, CEO & Director |
James M. Frates | 55 | 2014 | Independent Director |
Michael F. Cola | 62 | 2014 | Independent Director |
Charles Zorumski | - | - | Member of Scientific Advisory Board |
Steven M. Paul | 73 | 2011 | Independent Director |
Stephen Moss | - | - | Member of Scientific Advisory Board |
Donald Stein | - | - | Member of Scientific Advisory Board |
David H. Farb | - | - | Member of Scientific Advisory Board |
Elizabeth A. Barrett | 62 | 2019 | Independent Director |
George S. Golumbeski | 67 | 2019 | Independent Director |
Stephen F. Traynelis | - | - | Member of Scientific Advisory Board |
Christine Marx | - | - | Member of Scientific Advisory Board |
Scott Runyon | - | - | Member of Scientific Advisory Board |
A. Leslie Morrow | - | - | Member of Scientific Advisory Board |
Michael A. Rogawski | - | - | Member of Scientific Advisory Board |
Jeffrey M. Jonas | 71 | 2013 | Outside Non-Employee Member of CNS Innovation Advisory Board & Director |
James E. Audia | 68 | - | Member of Scientific Advisory Board |
Jessica J. Federer | 41 | 2023 | Independent Director |
Geno J. Germano | 63 | 2016 | Independent Chair of the Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核